🇺🇸 FDA
Patent

US 11338041

Exon skipping oligomer conjugates for muscular dystrophy

granted A61KA61K47/6455A61K47/6807

Quick answer

US patent 11338041 (Exon skipping oligomer conjugates for muscular dystrophy) held by Sarepta Therapeutics, Inc. expires Mon May 19 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Sarepta Therapeutics, Inc.
Grant date
Tue May 24 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 19 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
22
CPC classes
A61K, A61K47/6455, A61K47/6807, A61K9/0019